Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 7/20 | 0.58 |
| ▸ | CA9 | Q16790 | 7/20 | 0.58 |
| ▸ | CA4 | P22748 | 6/20 | 0.58 |
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | CA2 | P00918 | 2/20 | 0.58 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.58 |
| ▸ | CA7 | P43166 | 1/20 | 0.58 |
| ▸ | MAOA | P21397 | 7/20 | 0.49 |
| ▸ | MAOB | P27338 | 7/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5704167 | 0.88 | CA12 (0.63) | CA12CA9CA4CA1CA2 | |
| Hydrochloric Acid SCHEMBL21694040 | 0.85 | CA12 (0.61) | CA12CA9CA4CA1CA2 | |
| SCHEMBL9155218 | 0.81 | GSTP1 (0.68) | CA12CA9CA4CA1CA2 | |
| SCHEMBL15800551 | 0.81 | CA12 (0.57) | CA12CA9CA4CA1CA2 | |
| SCHEMBL5684218 | 0.79 | GSTP1 (0.60) | CA12CA9CA4CA1CA2 | |
| SCHEMBL126399 | 0.77 | CA12 (0.53) | CA12CA9CA4CA1CA2 | |
| SCHEMBL975819 | 0.77 | CA12 (0.53) | CA12CA9CA4CA1CA2 | |
| SCHEMBL22388776 | 0.77 | CA12 (0.53) | CA12CA9CA4CA1CA2 | |
| SCHEMBL5981846 | 0.77 | CA12 (0.53) | CA12CA9CA4CA1CA2 | |
| SCHEMBL126400 | 0.77 | CA12 (0.58) | CA12CA9CA4CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1807436-B1 | HETEROBIFUNCTIONAL POLY(ETHYLENE GLYCOL) AND USES THEREOF | INTEZYNE TECHNOLOGIES INC (US) | 2014-06-18 | — | — | EP | disclosed |
| EP-2502941-A1 | Heterobifunctional poly (ethylene glycol) and uses thereof | Intezyne Technologies Inc. (US) | 2012-09-26 | — | — | EP | disclosed |
| US-8268936-B2 | Synthesis of hybrid block copolymers and uses thereof | INTEZYNE TECHNOLOGIES, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20120196989-A1 | SYNTHESIS OF HOMOPOLYMERS AND BLOCK COPOLYMERS | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2012-08-02 | — | — | US | disclosed |
| EP-2348096-A2 | Synthesis of hybrid block copolymers and uses thereof | Intezyne Technologies Inc. (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20110124840-A1 | Synthesis of Homopolymers and Block Copolymers | INTEZYNE TECHNOLOGIES, INC. | 2011-05-26 | — | — | US | disclosed |
| US-20110021718-A1 | SYNTHESIS OF HYBRID BLOCK COPOLYMERS AND USES THEREOF | INTEZYNE TECHNOLOGIES (US) | 2011-01-27 | — | — | US | disclosed |
| US-7612153-B2 | conjugate polymer drugs; endcapped polyethers; nontoxic, biocompatible, non-immunogenic, soluble in water and other solvents | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-7601796-B2 | polyamideether copolymer has a hydrophilic polyethylene glycol and a hydrophobic polyamino acid blocks; modified polyethylene glycol homopolymer; forming conjugate polymer drug; resin peptides; use in pharmaceutically acceptable compositions | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| EP-1833958-A4 | SYNTHESIS OF HYBRID BLOCK COPOLYMERS AND USES THEREOF | INTEZYNE TECHNOLOGIES INC (US) | 2009-01-14 | — | — | EP | disclosed |
| EP-1848460-A2 | SYNTHESIS OF HOMOPOLYMERS AND BLOCK COPOLYMERS | Intezyne Technologies Incorporated (US) | 2007-10-31 | — | — | EP | disclosed |
| EP-1833958-A2 | SYNTHESIS OF HYBRID BLOCK COPOLYMERS AND USES THEREOF | Intezyne Technologies Incorporated (US) | 2007-09-19 | — | — | EP | disclosed |
| EP-1807436-A2 | HETEROBIFUNCTIONAL POLY(ETHYLENE GLYCOL) AND USES THEREOF | Intezyne Technologies Incorporated (US) | 2007-07-18 | — | — | EP | disclosed |
| WO-2006086325-A2 | SYNTHESIS OF HOMOPOLYMERS AND BLOCK COPOLYMERS | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2006-08-17 | — | — | WO | disclosed |
| US-20060172914-A1 | Synthesis of hybrid block copolymers and uses thereof | INTEZYNE TECHNOLOGIES, INC. | 2006-08-03 | — | — | US | disclosed |
| WO-2006074202-A2 | SYNTHESIS OF HYBRID BLOCK COPOLYMERS AND USES THEREOF | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2006-07-13 | — | — | WO | disclosed |
| US-20060142506-A1 | Heterobifunctional poly(ethylene glycol) and uses thereof | INTEZYNE TECHNOLOGIES, INC. | 2006-06-29 | — | — | US | disclosed |
| WO-2006047419-A2 | HETEROBIFUNCTIONAL POLY(ETHYLENE GLYCOL) AND USES THEREOF | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142506-A1 | Heterobifunctional poly(ethylene glycol) and uses thereof | GNE, ALG1, EPHX2 | CA12 1486/4885CA9 2309/4885CA4 1893/4885 |
| US-20110124840-A1 | Synthesis of Homopolymers and Block Copolymers | PARG, PCNA, PARN | CA12 1670/4885CA9 4161/4885CA4 1945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.